Akili, Inc.

Akili, Inc. (ticker: DNAA) is a digital therapeutics company that entered the public markets through a SPAC combination with Social Capital Suvretta Holdings Corp. One, a vehicle that completed its initial public offering in 2021. The SPAC was co-sponsored by Social Capital and Suvretta Capital Management and targeted the healthcare and life sciences sector. Akili develops prescription digital therapeutics, including EndeavorRx, the first video game authorized by the U.S. FDA as a treatment for attention-deficit/hyperactivity disorder in pediatric patients. In July 2024, the company submitted an 8-K current report to the Securities and Exchange Commission. Sign up at SpacDesk for full filing data, sponsor profiles, and real-time analytics across the SPAC universe.